Bluebird bio Inc (BLUE) Share Price Today, Stock Analysis, Annual Report | Value Research Bluebird bio Inc (BLUE) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.
  • Price Change
  • Market Capitalisation market-capitalisation-info $386 Mln

  • 12 Month Earnings monthly-earning $-155 Mln
  • Price to Earnings price-to-earning --

Bluebird bio Inc (BLUE) Share Price

$3.06

As on 27-Sep-2023 16:00 EDT

up-down-arrow $-0.02-0.65%

  • Prev Close info

    $3.08

  • Day's Openinfo

    $3.08

  • Today's Highinfo

    $3.19

  • Today's Lowinfo

    $2.99

  • Today's Volumeinfo

    1,947,572

Please wait...

Bluebird bio Inc (BLUE) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Bluebird bio Inc (BLUE)
-55.78 -11.82 -5.56 -40.70 -56.40 -49.17 -15.63
S&P BSE Sensex*
7.67 0.96 3.30 14.71 20.56 12.52 12.75
#
-- -- -- -- -- -- --
As on 27-Sep-2023  |  *As on 28-Sep-2023  |  #As on
2022
2021
2020
2019
2018
2017
2016
Bluebird bio Inc (BLUE)
-30.73 -64.34 -50.69 -11.54 -44.12 188.65 -3.92
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Bluebird bio Inc (BLUE) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Bluebird bio Inc (BLUE)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Pres, CEO & Director

        Mr. Andrew Obenshain

        Chief Commercial Officer & COO

        Mr. Thomas J. Klima

        Headquarters

        Cambridge, MA

        FAQs for Bluebird bio Inc (BLUE)

        The total asset value of Bluebird bio Inc (BLUE) stood at $ 809 Mln as on 31-Mar-23

        The share price of Bluebird bio Inc (BLUE) is $3.060000 (NASDAQ) as of 27-Sep-2023 16:00 EDT. Bluebird bio Inc (BLUE) has given a return of -56.4% in the last 3 years.

        Bluebird bio Inc (BLUE) has a market capitalisation of $ 386 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Bluebird bio Inc (BLUE) is 4.37 times as on 02-Jun-2023, a 0.72% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Bluebird bio Inc (BLUE) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Bluebird bio Inc (BLUE) and enter the required number of quantities and click on buy to purchase the shares of Bluebird bio Inc (BLUE).

        bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

        The CEO & director of Mr. Andrew Obenshain. is Bluebird bio Inc (BLUE), and CFO & Sr. VP is Mr. Thomas J. Klima.

        The promoters of Bluebird bio Inc (BLUE) have pledged 0% of the total equity as on Mar-23.

        Bluebird bio Inc (BLUE) Ratios
        Return on equity(%)
        -40.16
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Bluebird bio Inc (BLUE) was $-155 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $386.28 Mln
        • Revenue (TTM)revenue-information $4.03 Mln
        • Earnings (TTM) earning-information $-155.42 Mln
        • Cash date-information $318.26 Mln
        • Total Debt info $273.38 Mln
        • Insider's Holding 1.04%
        • Liquidity liquidity High
        • 52 Week range week-range $2.78 - 8.58
        • Shares outstanding share-outstanding 106,412,000
        • 10 Years Aggregate:

          CFO: $-3,021.63 Mln

          EBITDA: $-3,602.05 Mln

          Net Profit: $-3,633.11 Mln

        About The Company

        • IPO Date 19-Jun-2013
        • Pres, CEO & Director Mr. Andrew Obenshain
        • Chief Commercial Officer & COO Mr. Thomas J. Klima
        • Listing key-listing NASDAQ: BLUE
        • Country United States
        • Headquarters headquarters Cambridge, MA
        • Website website https://www.bluebirdbio.com
        • Business

          bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of...  transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon